secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-034975
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026
--------------------------------------------------------------------------------

- ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.
- Net loss $36.5M ($0.38/sh) vs $48.9M ($0.60/sh) in Q2 2023; adjusted net loss $24.4M ($0.25/sh).
- Cash $300.1M after $97.4M May 2024 offering; runway extended into mid-2026.
- LOTIS-5 Phase 3 IDMC recommended continue; full enrollment expected before year-end 2024.
- LOTIS-7 dose expansion on track; safety/efficacy data expected year-end 2024, mature data H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024034975/0001628280-24-034975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828024034975/adc-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-034975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer